David Shapiro Sells 3,545 Shares of Intercept Pharmaceuticals Inc. (ICPT) Stock
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) CMO David Shapiro sold 3,545 shares of the business’s stock in a transaction on Monday, September 26th. The shares were sold at an average price of $165.08, for a total transaction of $585,208.60. Following the transaction, the chief marketing officer now directly owns 45,732 shares in the company, valued at $7,549,438.56. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
David Shapiro also recently made the following trade(s):
- On Tuesday, July 5th, David Shapiro sold 163 shares of Intercept Pharmaceuticals stock. The shares were sold at an average price of $145.11, for a total transaction of $23,652.93.
Shares of Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) opened at 160.23 on Friday. The stock’s market cap is $3.96 billion. Intercept Pharmaceuticals Inc. has a 52-week low of $89.76 and a 52-week high of $217.99. The stock’s 50 day moving average is $158.82 and its 200 day moving average is $149.05.
Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($3.14) EPS for the quarter, beating the consensus estimate of ($3.69) by $0.55. The firm had revenue of $5.52 million for the quarter, compared to analyst estimates of $1.72 million. Intercept Pharmaceuticals had a negative return on equity of 50.58% and a negative net margin of 5,003.95%. The business’s revenue for the quarter was up 1140.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.99) earnings per share. On average, equities analysts predict that Intercept Pharmaceuticals Inc. will post ($16.31) EPS for the current fiscal year.
Several institutional investors have recently made changes to their positions in ICPT. Aperio Group LLC raised its position in shares of Intercept Pharmaceuticals by 31.2% in the first quarter. Aperio Group LLC now owns 2,152 shares of the biopharmaceutical company’s stock valued at $276,000 after buying an additional 512 shares in the last quarter. BlackRock Inc. raised its position in Intercept Pharmaceuticals by 301.5% in the first quarter. BlackRock Inc. now owns 1,915 shares of the biopharmaceutical company’s stock valued at $246,000 after buying an additional 1,438 shares during the period. BlackRock Group LTD raised its position in Intercept Pharmaceuticals by 20.1% in the first quarter. BlackRock Group LTD now owns 13,074 shares of the biopharmaceutical company’s stock valued at $1,680,000 after buying an additional 2,188 shares during the period. BlackRock Fund Advisors raised its position in Intercept Pharmaceuticals by 7.2% in the first quarter. BlackRock Fund Advisors now owns 467,272 shares of the biopharmaceutical company’s stock valued at $60,030,000 after buying an additional 31,289 shares during the period. Finally, Marcus Capital LLC bought a new position in Intercept Pharmaceuticals during the first quarter valued at about $1,317,000. Hedge funds and other institutional investors own 81.86% of the company’s stock.
A number of research analysts have issued reports on the stock. Wedbush reissued an “outperform” rating and set a $239.00 price objective on shares of Intercept Pharmaceuticals in a research report on Monday, July 25th. Robert W. Baird reissued an “outperform” rating and set a $332.00 price objective on shares of Intercept Pharmaceuticals in a research report on Wednesday, June 15th. Credit Suisse Group AG reissued a “buy” rating and set a $200.00 price objective on shares of Intercept Pharmaceuticals in a research report on Friday, August 5th. Vetr downgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $81.50 price objective on the stock. in a research report on Monday, August 8th. Finally, Oppenheimer Holdings Inc. reduced their price objective on shares of Intercept Pharmaceuticals from $265.00 to $250.00 and set an “outperform” rating on the stock in a research report on Friday, August 5th. Five research analysts have rated the stock with a sell rating, five have issued a hold rating and ten have given a buy rating to the company. Intercept Pharmaceuticals presently has an average rating of “Hold” and an average price target of $177.67.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.